Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

LUDWIG, Heinz, Roman HÁJEK, Elena TÓTHOVÁ, Johannes DRACH, Zdeněk ADAM, Boris LABAR, Miklós EGYED, Ivan ŠPIČKA, Heinz GISSLINGER, Richard GREIL, Ingrid KUHN, Niklas ZOJER and Axel HINKE. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood. Washington, DC, USA: The American Society of Hematology, 2009, vol. 113, No 15, p. 3435-3442. ISSN 0006-4971.

Basic information

• Original name: Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
• Name in Czech: Srovnání léčby Thalidomid-dexamethason s melphalan-prednison u pacientů s mnohočetným myelomem
• Authors: LUDWIG, Heinz (40 Austria), Roman HÁJEK (203 Czech Republic, guarantor), Elena TÓTHOVÁ (703 Slovakia), Johannes DRACH (40 Austria), Zdeněk ADAM (203 Czech Republic), Boris LABAR (191 Croatia), Miklós EGYED (348 Hungary), Ivan ŠPIČKA (203 Czech Republic), Heinz GISSLINGER (40 Austria), Richard GREIL (40 Austria), Ingrid KUHN (40 Austria), Niklas ZOJER (40 Austria) and Axel HINKE (276 Germany).
• Edition: Blood, Washington, DC, USA, The American Society of Hematology, 2009, 0006-4971.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: United States of America
• Confidentiality degree: is not subject to a state or trade secret
• Impact factor: Impact factor: 10.555
• RIV identification code: RIV/00216224:14110/09:00035390
• Organization unit: Faculty of Medicine
• UT WoS: 000265052300008
• Keywords (in Czech): mnohočetný myelom; thalidomid
• Keywords in English: multiple myeloma; thalidomide; dexamethasone; melphalane; prednisone
• Tags: dexamethasone, melphalane, multiple myeloma, prednisone, Thalidomide
• Tags: International impact, Reviewed

Abstract

We compared thalidomide-dexamethasone with melphalan-prednisolone in 289 elderly patients with multiple myeloma. This is the first trial to compare TD with MP in elderly patients. Results in the TD group showed a significantly higher rate of very good responses (CR and VGPR) and significantly shorter time to response with no difference in time to progression and in progression-free survival.

Abstract (in Czech)

V článku je dokumentován výsledek první srovnávací studie léčby thalidomid-dexamethason s léčbou melphalan-prednisone.

Links

• LC06027, research and development project: Name: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)

Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group

• MSM0021622434, plan (intention): Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií

Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies